- HDACs is a class of enzymes that
regulate deacetylation of cellular proteins.
HDAC6, a member of class IIB, is mainly localized in cytoplasm and deacetylates non-histone proteins,
unlike other HDACs.
In this way, HDAC6 regulates various cellular processes including cell growth, cell migration, intracellular
transport, and even cell death.
Moreover, HDAC6 plays a role in the clearance of ubiquitinated proteins by its ubiquitin-binding domain.
Chong Kun Dang Research Institute have been focusing on developing HDAC6 inhibitors as drugs for various diseases related in eurology, oncology, immunology by the platform technology based on various scaffolds.
HDAC6 설명 Neurology Improvement of cognition and motor function through enhancing axonal transport Oncology Cancer death by increasing endoplasmic reticulum stress
Cancer immunotherapy through regulation of PD-L1 expression
Immunology Treatment of autoimmune diseases through anti-inflammation
- LIQUID CRYSTAL
- Liquistal® is a Chong Kun Dang’s platform
technology to develop sustained release
injectables by maintaining the effect of drug from
a week to several months after a single injection.
Liquistal® is a liquid formulation containing a drug for injection,
and it is transformed to a gel when contacted with body fluids after subcutaneous injection.
The gel formed after subcutaneous injection possesses a lattice structure like a honeycomb and
allows the drug to be released steadily over extended period. Currently, PLGA is the only material for
sustained release injection with FDA approval, but it has problems with the fact that manufacturing
process is not simple and that inflammatory response and pain can occur by PLGA injection.
Liquistal® is the technology which overcomes such shortcomings of PLGA, and it offers a simple
manufacturing process, improved sustainability and safety. Also it can be applied to the delivery
of various kinds of drugs including chemicals, proteins and peptides.
The safety of Liquistal® formulations was confirmed through preclinical studies,
and a phase I clinical trial is currently underway.